🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion.

    Alnylam Netherlands B.V.

    Hereditary Transthyretin Amyloidosis

    phase 3 small molecule active

    1 trial

  2. Amyvid 1900 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Trontinemab, Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, [18F]MK-6240

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial

  3. An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

    CORCEPT THERAPEUTICS INC

    Endogenous Cushing Syndrome

    phase 3 other active

    1 trial

  4. An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 3 other active

    1 trial

  5. An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)

    Boehringer Ingelheim

    Schizophrenia

    phase 3 other active

    1 trial

  6. Anakinra 100mg and Placebo Depo-Medrone

    United Therapeutics Europe Ltd

    Gout

    phase 3 small molecule completed

    1 trial

  7. Analatro

    Ultragenyx UK Limited

    Latrodectism

    phase 3 small molecule completed

    1 trial

  8. Angoron 150 mg/3 ml amp ενέσιμο διάλυμα, FLECARDIA Διάλυμα για ένεση/έχχυση

    Lacuna Pharma Pty Ltd

    Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%

    phase 3 small molecule active

    1 trial

  9. Anidulafungin

    Pfizer

    Candidemia

    phase 3 small molecule completed

    1 trial

  10. Anifrolumab, Anifrolumab Placebo

    AstraZeneca AB

    Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria

    phase 3 small molecule active

    1 trial

  11. Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

    AstraZeneca AB

    Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  12. Anti C5 Complement mAb Placebo, Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion Europe SAS

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  13. Anti C5 Complement mAb Placebo, Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  14. Anti-PD-1 antibody drug named Serplulimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Rectal Cancer (LARC)

    phase 3 small molecule active

    1 trial

  15. Anti-thymocyte globulin

    Ultragenyx UK Limited

    Aplastic Anemia

    phase 3 small molecule completed

    1 trial

  16. Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  17. Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

    Baxalta Innovations GmbH

    Hemophilia A

    phase 3 mab completed

    1 trial

  18. Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)

    Takeda

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  19. Antiplatelet (Aspirin, Dipyridamole, clopidogrel)

    United Therapeutics Europe Ltd

    Cervical Artery Dissection

    phase 3 small molecule completed

    1 trial

  20. Apalutamide

    Janssen Cilag International NV

    Metastatic Castrate-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  21. Apremilast 20mg

    Amgen

    Psoriatic Arthritis

    phase 3 small molecule completed

    1 trial

  22. Apremilast, Apremilast, Apremilast

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  23. Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

    Amgen

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  24. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources